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Helicobacter pylori virulence factor CagA
promotes tumorigenesis of gastric cancer
via multiple signaling pathways
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Abstract
Helicobacter pylori (H. pylori) infection is strongly associated with the development of gastric diseases but also with
several extragastric diseases. The clinical outcomes caused by H. pylori infection are considered to be associated
with a complex combination of host susceptibility, environmental factors and bacterial isolates. Infections involving
H. pylori strains that possess the virulence factor CagA have a worse clinical outcome than those involving CagA-negative
strains. It is remarkable that CagA-positive H. pylori increase the risk for gastric cancer over the risk associated with H. pylori
infection alone. CagA behaves as a bacterial oncoprotein playing a key role in H. pylori-induced gastric cancer. Activation
of oncogenic signaling pathways and inactivation of tumor suppressor pathways are two crucial events in the
development of gastric cancer. CagA shows the ability to affect the expression or function of vital protein in
oncogenic or tumor suppressor signaling pathways via several molecular mechanisms, such as direct binding or
interaction, phosphorylation of vital signaling proteins and methylation of tumor suppressor genes. As a result,
CagA continuously dysregulates of these signaling pathways and promotes tumorigenesis. Recent research has
enriched our understanding of how CagA effects on these signaling pathways. This review summarizes the results
of the most relevant studies, discusses the complex molecular mechanism involved and attempts to delineate
the entire signaling pathway.
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Introduction
Helicobacter pylori (H. pylori) is the most common human
pathogen worldwide, infecting an estimated 50 % of the
global population [1]. During H. pylori infection, sustained
inflammation and abnormal epithelial proliferation may
be major factors that lead to H. pylori-associated gastric
diseases, such as gastritis, peptic ulcers, mucosa-
associated lymphoid tissue lymphoma and gastric cancer.
Further studies have indicated that H. pylori is responsible
for several extragastric diseases, such as iron deficiency
anemia and idiopathic thrombocytopenic purpura [1, 2].
Interesting associations have also been noted between H.
pylori and other extragastric diseases, such as cardiovascu-
lar, neurological, hepatobiliary, colonic and pancreatic
diseases [2]. However, gastric cancer is one of the most
malignant types of tumor and represents a major health
problem worldwide. The association of H. pylori with gas-
tric cancer has received a great deal of attention and has
been thoroughly studied. The World Health Organization
and the International Agency for Research declared H.
pylori to be a Group I human carcinogen for gastric can-
cer in 1994, and a prospective cohort study further im-
plied that H. pylori is a necessary cause of gastric cancer
[3]. H. pylori also affects the prognosis of gastric cancer.
Fukase et al. performed a multi-center, open-label, ran-
domized controlled trial to clarify that eradication of H.
pylori should be performed after endoscopic resection of
early gastric cancer to prevent the development of meta-
chronous gastric cancer [4].
The majority of the H. pylori-infected population
remains asymptomatic, and few individuals may develop
gastric cancer. As the clinical outcomes caused by H.
pylori infection are considered to be associated with a
complex combination of host susceptibility, environmen-
tal factors and bacterial isolates [5]. The H. pylori
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genome shows genetic diversity among distinct isolates,
and H. pylori pathogenicity is different in distinct iso-
lates. Bacterial virulence factors exert an important
influence in determining the clinical outcomes, and
clinically isolated H. pylori strains are therefore classified
according to bacterial virulence factors. The strongest
candidates include the cag pathogenicity island (cag PAI)
and vacuolating cytotoxin A (VacA). Clinically isolated
H. pylori strains are often subdivided into two types ac-
cording to the cag PAI-encoded cytotoxin-associated
gene A (CagA) protein. Infections involving H. pylori
strains that possess a functional cag PAI confer a higher
risk for gastric cancer than those involving cag-negative
strains [6]. The cag PAI is a 40 kb DNA fragment that
encodes the CagA protein and functional components of
a type IV secretion system (T4SS). The CagA protein,
which is injected into gastric epithelial cells through the
T4SS, behaves as a bacterial oncoprotein [7]. Ohnishi N
et al. generated CagA transgenic mice that showed a
significant increase in the incidence of gastric cancer.
These results provide first direct evidence of the role of
CagA as a bacterial oncoprotein that acts in mammals
[8]. Meta-analyses further indicates that individuals
infected with CagA-positive strains of H. pylori show an
increased risk for gastric cancer over the risk associated
with H. pylori infection alone [9, 10].
The molecular mechanism underlying CagA-positive
H. pylori-induced gastric cancer has been widely studied.
Translocation of CagA into gastric epithelial cells is the
first step in the processes of CagA-induced tumorigen-
esis. Several different Cag proteins are involved in the
translocation of CagA. One of these proteins, CagL,
functions as a component of the T4SS that binds to and
activates α5β1 integrin receptors, triggering the delivery
of the bacterial effector protein CagA to the cytoplasm
of host cells [11]. Additional Cag proteins (CagY, CagI,
CagA) have also been shown to bind β1 integrin and
permit translocation of the bacterial effector protein
CagA [12, 13]. Another structural component, CagE, was
reported to be essential for CagA translocation. Further-
more, infection with H. pylori can induce phosphatidylser-
ine (PS) externalization in epithelial cells, and CagA then
interacts with the externalized PS to initiate its entry into
cells [14]. Collectively, these findings indicate that H. pyl-
ori exploits host cell surface molecules such as integrins
and PS to deliver CagA to the host cells. Additionally,
CagA translocation requires energy-dependent host cell
processes distinct from endocytic pathways. Cytomem-
brane cholesterol and actin polymerization are also neces-
sary for CagA translocation [14].
Once the protein has entered these target cells, parts
of CagA molecules are tyrosine-phosphorylated by Src
and Abl family kinases within several repeat Glu-Pro-
Ile-Tyr-Ala (EPIYA) motifs, while other CagA molecules
remain unphosphorylated [15–17]. CagA then binds to
various signaling proteins and causes dysregulation of
multiple signaling pathways in either a phosphorylation-
dependent or phosphorylation-independent manner [18].
Phosphorylated CagA causes epithelial cells elongation
and scattering, a morphology was originally referred to as
the “hummingbird phenotype”, due to its effect on host
cell signaling pathways, such as the extracellular signal-
regulated kinase (ERK)/mitogen-activated protein kinase
(MAPK) pathway, by interacting with SHP2, Grb2 and
Crk/Crk-L [19, 20]. On the other hand, unphosphorylated
CagA interacts with various signaling proteins, such
as Met, E-cadherin, Grb2 and Par1b, and then acti-
vates corresponding signaling pathways, such as the
phosphatidylinositol 3-kinase/Akt (PI3K/Akt) signaling
pathway, nuclear factor-κB (NF-κB) signaling pathway,
Wnt/β-catenin signaling pathway and Ras signaling path-
way, among others [21–23]. These interactions and the
activation of these signaling pathways contribute to the
epithelial proliferation and pro-inflammatory processes as
well as the disruption of cell-to-cell junctions, or loss of
cell polarity.
This review focuses on recent findings regarding
CagA, related to various kinds of vital signaling pro-
teins and several classic signaling pathways. In combin-
ation with previous studies on corresponding proteins or
signaling pathways, we hope to discuss the possible mo-
lecular mechanism underlying the CagA-induced abnor-
mal expression of vital signaling proteins and the
dysregulation of signaling pathways, and to further
recognize the relationship of CagA and the clinical out-
comes of H. pylori infection, especially gastric cancer,
which is the most severe outcome.
CagA mediates dysregulation of the Wnt/β-catenin
signaling pathway
The Wnt/β-catenin signaling pathway is a key pathway
regulating embryonic development and adult tissue
homeostasis. Aberrant Wnt/β-catenin signaling plays an
essential role in disease pathogenesis, especially in tumori-
genesis and progression [24, 25]. The Wnt/β-catenin sig-
naling pathway is highly conserved among species, and
the core of this pathway is the versatile protein β-catenin,
encoded by CTNNB1. The canonical Wnt/β-catenin sig-
naling pathway is activated by a secreted extracellular
Wnt ligand that binds to frizzled (Fzd) receptors and their
co-receptors the low-density lipoprotein receptor related
protein (LRP) families. The activated Fzd receptor
switches on the intracellular signaling cascade. Then the
phosphorylation of LRP activates the disheveled protein
(Dvl), which in turn inactivates a complex of proteins col-
lectively termed the “destruction complex”, including the
core proteins glycogen synthase kinase-3β (GSK-3β), Axin,
adenomatosis polyposis coli (APC) and casein kinase-1
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(CK-1). In the absence of Wnt ligands or the presence
of abundant competitive ligands, such as Wnt inhibi-
tory factor-1(WIF-1), secreted Frizzled related proteins
(sFRPs), or Dickkopf family proteins (DKKs), the de-
struction complex phosphorylates the N-terminus of
cytosolic β-catenin, and targets it for proteasomal deg-
radation, thereby maintaining β-catenin at low baseline
cytosolic levels. However, in the presence of Wnt ligands,
cytosolic β-catenin can not be phosphorylated due to
inactivation of the destruction complex. As a result, β-
catenin is stabilized and accumulates in the cytoplasm and
subsequently translocates to the nucleus. In the nucleus,
β-catenin interacts with the T cell factor/lymphoid enhan-
cer factor (TCF/LEF) family of transcription factors to
induce target gene transcription [26, 27].
Dysregulation of the Wnt/β-catenin signaling pathway
is widely implicated in gastrointestinal cancers, including
colorectal cancer and gastric cancer [27, 28]. Mutation
of pathways components (eg. Axin and β-catenin), inhib-
ition of antagonists (eg. sFRPs) or crosstalk with other
signaling pathways leads to continuous dysregulation of
the Wnt/β-catenin signaling pathway. Infection by
Pathogenic microorganisms, such as H. pylori, Hepatitis
virus, is another important factor influencing the Wnt/
β-catenin signaling pathway [29–33]. Franco et al. re-
ported that CagA-positive H. pylori altered β-catenin
localization and increased β-catenin nuclear accumula-
tion in gastric epithelial cells AGS. Along with β-catenin
nuclear translocation, the Wnt/β-catenin signaling path-
way is activated. These authors also observed this
phenomenon in gerbil gastric mucosae and human gas-
tric mucosae colonized by CagA-positive H. pylori [29].
Another study further confirmed that the nuclear trans-
location of β-catenin and subsequent activation of the
Wnt/β-catenin signaling by CagA required the EPIYA
repeat region and was independent of CagA tyrosine
phosphorylation [30]. Neal et al. generated transgenic
zebrafish expressing CagA and found the Wnt/β-catenin
target genes significant upregulation in the transgenic
zebrafish. The functional consequences of the CagA-
activated Wnt/β-catenin signaling pathway included in-
creased intestinal proliferation. These results provided in
vivo evidence of CagA-induced Wnt/β-catenin signaling
pathway activation [31].
Under physiological conditions, β-catenin interacts
with the cytoplasmic tail of E-cadherin to form adherens
junctions between epithelial cells. However, upon infec-
tion with CagA-positive H. pylori strains, CagA will be-
come competitive in combination with E-cadherin and
disrupt complex formation between E-cadherin and β-
catenin, causing cytoplasmic and nuclear accumulation
of β-catenin. In addition, the interaction between CagA
and E-cadherin is independent of CagA tyrosine phos-
phorylation, but the specific binding sites involved are
not clear (Fig. 1a) [22]. Therefore, they may be directly
bound or indirectly bound via another component of the
adherens junction complex. Although the details of the
interaction between CagA and E-cadherin remain to be
elucidated, this research provided the molecular mech-
anism of CagA deregulation of β-catenin and subsequent
activation of the canonical Wnt/β-catenin signaling
pathway. AGS gastric epithelial cells are commonly used
in the study of H. pylori because these cells are highly
susceptive to H. pylori infection. Interestingly, AGS do
not form E-cadherin/β-catenin complexes due to a lack
of E-cadherin expression, and CagA is therefore not
able to release of β-catenin from the E-cadherin/β-catenin
compelx. Nevertheless, CagA still increases the cyto-
plasmic and nuclear accumulation of β-catenin in AGS
cells and activates the Wnt/β-catenin signaling pathway
[21, 29]. Thus, there may be other mechanisms through
which CagA regulates β-catenin and the Wnt/β-catenin
signaling pathway.
Wnt ligands/receptors or the components of the de-
struction complex may be involved in the CagA-positive
H. pylori-induced activation of the Wnt/β-catenin sig-
naling pathway. It has been reported H. pylori induces
rapid activation of the Wnt/β-catenin signaling pathway
co-receptor LRP6, which is dependent on proteins of
Dvl family (Fig. 1b) [34]. Although this process was
found to be independent of CagA, H. pylori lacking a
functional T4SS failed to induce LRP6 phosphorylation
and activation. It is still unclear how H. pylori activates
LRP6 and whether there is a direct relationship between
H. pylori and Dvl. Sokolova et al. reported that H. pylori
suppressed GSK-3β activity to promote β-catenin activity
in a CagA-independent manner [35]. Subsequently,
Nakayama et al. reported that H. pylori VacA induced
the phosphorylation and inactivation of GSK-3β through
the PI3K/Akt signaling pathway, and subsequent nuclear
translocation of β-catenin regulated transcriptional activ-
ity [36]. Tabassam et al. came to a similar conclusion,
that H. pylori induced GSK-3β inactivation via the PI3K/
Akt signaling pathway, but their results showed that
CagA was responsible for GSK-3β inactivation and
downstream β-catenin activation (Fig. 1c) [37]. These
opposing results may be due to the differences in the cell
lines and H. pylori strains used in the research. Sokolova
et al. mainly employed MDCK cells and an H. pylori
strain P1 expressing CagA. They confirmed that CagA
could be translocated and phosphorylated at tyrosine
residues in both AGS and MDCK cells, but they did not
verify the following results in AGS cells. Similarly,
Nakayama et al. only used the AZ-521 cell line in their
research, and this cell line has been used relatively less
frequently in research on H. pylori. Recently, Korean re-
searchers explained H. pylori CagA-induced GSK-3β in-
activation from another perspective. They indicated that
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CagA could directly bind GSK-3β and deplete GSK-3β
activity. Furthermore, they found that the C-terminal re-
gion of CagA harbored an EPIYA motif and a multimeri-
zation domain that played an important role in the
binding and depletion of GSK-3β (Fig. 1d) [38]. This re-
sult is consistent with previous findings showing that the
EPIYA repeat region is responsible for β-catenin activa-
tion [30]. Taken together, these results show that CagA
mediates dysregulation of the Wnt/β-catenin signaling
pathway via effecting the release and degradation of β-
catenin.
CagA activates PI3K/Akt and the downstream signaling
pathways
PI3K, which is involved in tumorigenesis, is a heterodi-
mer consisting of a p85 regulatory subunit and a p110
catalytic subunit. The main function of PI3K is to phos-
phorylate phosphatidylinositol in the cytomembrane and
convert it into phosphatidylinositol 3, 4, 5-triphosphate
(PIP3). PIP3 interacts with the pleckstrin homology (PH)
domain of a ser/thr kinase Akt and allows Akt phos-
phorylation at Ser473 or Thr308. This phosphorylation
activates Akt, which in turn, activates or inactivates
downstream tyrosine kinase- and G-protein-coupled re-
ceptors in turn. GSK-3β, NF-κB and mammalian target
of rapamycin (mTOR) are key representative of PI3K/
Akt downstream target proteins [37, 39–44], and the
MEK/ERK signaling pathway is a representative of PI3K/
Akt downstream signaling pathway [45].
The PI3K/Akt signaling pathway is hyperactive in
some cancers, including gastric cancer [46, 47]. H. pylori
infection is a major factor in the activation of PI3K/Akt
and downstream signaling pathways [21, 37, 44]. The ac-
tivation of PI3K/Akt signaling pathways is a response to
growth factors (eg. epidermal growth factor, hepatocyte
growth factor). As the specific receptors of epidermal
growth factor and hepatocyte growth factor, the epider-
mal growth factor receptor (EGFR) and c-met, respect-
ively, mediate the activation of the PI3K/Akt signaling
pathway. H. pylori infection induces the phosphorylation
Fig. 1 CagA mediates dysregulation of the Wnt/β-catenin signaling pathway. a. CagA competitively combines with E-cadherin and disrupts the
E-cadherin/β-catenin complex formation, causing cytoplasmic and nuclear accumulation of β-catenin. b. H. pylori induces rapid phosphorylation
and activation of LRP6. c. CagA induces GSK-3β inactivation via the PI3K/Akt signaling pathway. d. CagA binds GSK-3β directly and depletes GSK-3β
activity, inhibiting the phosphorylation and proteasomal degradation of cytosolic β-catenin
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of EGFR Tyr 992 and the transactivation of EGFR, which
is dependent on CagA and another virulence factor,
OipA. As a result, the PI3K p85 subunit is activated, and
two specific phosphorylation sites (Thr 308 and Ser 473
of Akt) are phosphorylated. Importantly, the CagA mu-
tation reduces the activation of Akt Thr 308, whereas
the oipA mutation reduces the levels of Akt Ser 473 in
response to H. pylori infection. Double CagA/OipA mu-
tation results in complete inhibition of the phosphoryl-
ation of Akt Ser 473, confirming that CagA mainly
affects the phosphorylation of Akt Ser 473 [37]. Interest-
ingly, EGFR is activated by H. pylori during early infec-
tion, but H. pylori CagA inactivates EGFR during
prolonged infection via reducing the phosphorylation of
EGFR tyrosine residues [48]. This research revealed that
CagA-positive H. pylori regulates EGFR activation and
inactivation to support persistent infection. But it is regret-
table that the EGFR/PI3K/Akt signaling pathway is not
mentioned in this paper. Thus, the role of EGFR in H. pyl-
ori-induced signaling pathways is not completely clear and
needs to be investigated more thoroughly in the future.
However, it has been confirmed that c-met is activated in
H. pylori-infected conditions, and CagA is able to interact
with activated c-met [21, 49] Moreover, the C-terminal re-
gion of CagA, which is designated CRPIA (conserved re-
peat responsible for phosphorylation-independent activity),
is involved in the interaction with c-met and the activation
of the downstream PI3K/Akt signaling pathway. As a re-
sults of CagA-induced PI3K/Akt signaling pathway activa-
tion, GSK3β, which is a downstream target of PI3K/Akt, is
inactivated, and β-catenin transcription is subsequently ac-
tivated [21, 37]. In other words, there is a crosstalk between
the CagA-induced Wnt/β-catenin signaling pathway and
the PI3K/Akt signaling pathway.
Recently, Zhang et al. found CagA EPIYA repeat
region was also involved in the activation of PI3K/Akt
signaling pathway [50]. The EPIYA repeat region of
CagA is classified into 4 tyrosine phosphorylation motifs
(TPMs), A-, B-, C- or D-TPMs. Western CagA has A-,
B-, and C-TPMs, while East Asian CagA possesses A-,
B-, and D-TPMs [51, 52]. Zhang et al. demonstrated
CagA activated PI3K/Akt signaling pathway by inter-
action with PI3K via a functional B-TPM. Through data-
base searching and silico analysis, they revealed a strong
non-random distribution of the B-TPM polymorphisms
(A/T polymorphism, including EPIYA and EPIYT) in
Western H. pylori isolates. And Matsunari et al. previ-
ously also reported that B-TPM polymorphisms (EPIYT,
EPIYA, ESIYA and so on) and that EPIYT of B-TPM
was more predominant in Western H. pylori isolates and
EPIYA of B-TPM was more predominant in East Asian
H. pylori isolates [53]. Interestingly, during co-culture
with AGS cells, an H. pylori strain with EPIYT B-TPM
had higher affinity to PI3K and significantly enhanced
induction of PI3K/Akt signaling pathway, compared to
the isogenic strain with EPIYA B-TPM [50]. These re-
sults suggest that the A/T polymorphisms in B-TMP
could regulate PI3K/Akt signaling pathway activity
through influencing the interaction between CagA and
PI3K. In addition, H. pylori strain with EPIYT B-TPM
induced less hummingbird cells and IL-8 levels than the
isogenic strain with EPIYA B-TPM [50]. In this regard,
the differential EPIYT and EPIYA functions might be
part of the reason that the incidence of gastric carcin-
oma is much higher in East Asian countries than in
Western countries. However, it is regrettable that there
is no direct result confirms the relationship between
PI3K/Akt signaling and hummingbird phenotype and
IL-8 levels. Indeed, it is difficult to use a simple linear
relationship to clarify the regulation of PI3K/Akt signal-
ing on hummingbird phenotype and IL-8 levels, because
(i) PI3K/Akt downstream target proteins or signaling
pathways are pleiotropic and have complex crosstalk
with other signaling pathways, (ii) H. pylori could induce
AGS hummingbird phenotype and IL-8 production
through multiple CagA-mediated mechanisms.
NF-κB, which is a downstream target of PI3K/Akt, is a
crucial regulator of many cellular processes, including
inflammation, immune responses and tumorigenesis.
NF-κB is a p65/p50 heterodimer that forms a complex
with cytoplasmic inhibitors (eg. IκB) in resting condition.
PI3K/Akt can activate IκB kinase (IKK), which phos-
phorylates IκB and subsequently releases NF-κB from
the complex. Then NF-κB translocates to the nucleus,
and phosphorylation of the p65 subunit plays a key role in
the NF-κB-mediated transcriptional response. It has been
accepted that H. pylori cag PAI is required for NF-κB acti-
vation [54, 55], but the role of CagA in the regulation of
NF-κB activity is still a subject of intense discussion. Early
studies found that H. pylori induced NF-κB activation in
time-, multiplicity of infection-, and cag PAI-dependent
manners [54]. Recently, Sokolova further confirmed that
H. pylori cag PAI encoding T4SS was required for activa-
tion of NF-κB and release of downstream IL-8, but CagA
had only a partial or minor role in NF-κB activation and
IL-8 release at early infection [55]. In contrast, Brandt et
al. found that CagA could activate NF-κB and induce
downstream IL-8 release in a time-dependent manner
[56]. In this study, CagA activates NF-κB and induces IL-8
induction via the MEK/ERK signaling pathway. Subse-
quently, Kim et al. constructed CagA and its fragments
eukaryotic expression vectors, and further confirmed that
NF-κB activation and IL-8 release induced by CagA
occurred via the MEK/ERK signaling pathway activation
[57]. Recently, Kang et al. compared different CagA-
positive and -negative H. pylori strains for their ability to
activation of NF-κB in different gastric cancer cells. They
confirmed that CagA was required for H. pylori-induced
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activation of NF-κB and that CagA selectively induced
Phospholipase D1 expression via NF-κB [58]. The different
H. pylori strains used by different laboratories may be re-
sponsible for different components of H. pylori that drive
NF-κB signaling pathway. However, the time point of H.
pylori infection may be the main factor determing which
component drive NF-κB signaling pathway. Most of the
previous studies compared different CagA-positive and
-negative H. pylori strains for their ability to activation of
NF-κB at early time points of infection (less than 3 h).
They found H. pylori induced NF-κB activation and IL-8
release in a CagA-independent manner [54, 55]. Interest-
ingly, during persistent infection (more than 12 h), NF-κB
activation and IL-8 release further increased in a CagA-
dependent manner [56, 58]. It is may be meaningful to ex-
plore how T4SS initiate NF-κB signaling pathway and how
CagA is involved in NF-κB activation during persistent
infection. Transforming growth factor-β-activated kinase 1
(TAK1) is a key regulator of signal transduction cascades
that lead to the activation of IKK and NF-κB. CagA phys-
ically interacts with TAK1 and enhances the activity of
TAK1, which is required for NF-κB activation by CagA
[59]. However, a later study has shown that this is a
misinterpretation because the antibody against TAK1
immunoprecipitated to some extent the CagA protein
by unknown reasons, while in a reverse immunoprecip-
itation using a CagA antibody they also could not
recognise co-immunoprecipitated TAK1 [60]. Although
they indicate TAK1 is not a target of the H. pylori
CagA, TAK1 is required for H. pylori-induced NF-κB
activation in a T4SS-dependent and CagA-independent
manner during early infection. Actually, H. pylori-in-
duced interaction between TAK1 and IKK complex
may be involved in NF-κB initial activation in a T4SS-
dependent manner during early infection, while CagA
may be play a role in extend the activation of NF-κB
during persistent infection because CagA takes more
time to be delivered into the host cells and regulates its
target proteins or signaling pathways. As mentioned in
the previous studies, CagA need more time to enhance
NF-κB activity and increase IL-8 release during persist-
ent infection [56, 58]. Therefore, further studies are
necessary to elucidate the mechanisms of H. pylori-
induced interaction between TAK1 and IKK complex
during early infection and the exact function of CagA
in the regulation of NF-κB activity during persistent
infection.
H. pylori CagA has the ability to activate of the PI3K/
Akt signaling pathway, but the regulation of the PI3K/
Akt downstream signaling pathways by H. pylori is still
not completely clear. As an upstream regulator of NF-
κB, PI3K/Akt is not mentioned in H. pylori-mediated ac-
tivation of NF-κB. Similarly, it has been reported that H.
pylori activates the PI3K/Akt/mTOR signaling pathway
in a CagA-independent manner [44]. As we mentioned
above, CagA and OipA can phosphorylate Akt and acti-
vate the PI3K/Akt signaling pathway, but only OipA is re-
quired for H. pylori-induced inactivation of the Forkhead
transcription factors of class O (FoxO) family members
FoxO1 and FoxO3a, which are the downstream of PI3K/
Akt [61]. These findings indicate that H. pylori can
activate PI3K/Akt and downstream signaling pathways via
different molecules and mechanisms, maintaining the
dysregulation of these signaling pathways and forming a
complex network.
The role of CagA in other oncogenic signaling pathways
Similar to the Wnt/β-catenin signaling pathway, the
Hedgehog (Hh) signaling pathway plays a critical role in
embryonic development, adult tissue homeostasis and
tumorigenesis [62]. H. pylori infection induces upregula-
tion of sonic hedgehog (Shh), which activates the Hh
signaling pathway in gastric cancer cells. Moreover, Shh
overexpression is CagA-dependent and is mediated
through the NF-κB signaling pathway [63]. Shh is mainly
expressed in parietal cells, influencing fundic gland dif-
ferentiation and function. Recently, Schumacher et al.
used a mouse model that expresses Shh fused to green
fluorescent protein, in place of wildtype Shh to visualize
Shh ligand expression in response to H. pylori infection in
vivo. They found that H. pylori induced Shh overexpression
in parietal cells that was consistent with the expression
pattern observed in the native tissue. Furthermore, they
confirmed that NF-κB signaling mediated H. pylori-induced
Shh overexpression and that CagA is involved in this
process [64]. In addition, in the early stages of H pylori in-
fection, H. pylori-induced Shh overexpression from parietal
cells acts as a macrophage chemoattractant to drive the in-
nate immune response during the initiation of gastritis [65].
Since it was first discovered, the c-Jun NH2-terminal
kinase (JNK) signaling pathway has been demonstrated
to exhibit both tumor suppressor and pro-tumorigenic
functions in different cell types and organs [66, 67]. In-
fection with H. pylori has been shown to activate the
JNK signaling pathway, and CagA is an important me-
diator of the activation of this signaling pathway during in-
fection [68, 69]. Wandler et al. used transgenic Drosophila
to express CagA, and they found that CagA triggered JNK
signaling pathway activation, which caused apoptosis in
epithelial cells. Interestingly, when these authors employed
a Ras oncogene-overexpression Drosophila metastasis
model, they found that coexpression of CagA could en-
hance the growth and invasive potential of tumor cells
through activation of the JNK signaling pathway [69]. This
finding indicates that, in addition to the presence of viru-
lence factors (eg. CagA), host genetics must also play an
important role in determining the outcome of H. pylori in-
fection. Indeed, H. pylori infection can persist for many
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years before the occurrence of gastric cancer. Therefore,
JNK-mediated apoptosis may be an effective mechanism
for limiting pathogenic effects and protecting the gastric
epithelium in early infection. Under persistent H. pylori
infection and the influence of other factors, accumulation
of genetic mutations is observed. Following the acquisition
of an oncogenic mutation, CagA-mediated JNK signaling
pathway activation promotes tumor progression. It will be
particularly valuable to further confirm the role of CagA-
mediated JNK signaling pathway activation in clinical tis-
sue samples, but there has been no report of such studies
to date.
Dysregulation of the Janus kinase (JAK)/signal trans-
ducers and activators of transcription 3 (STAT3) signal-
ing pathway is observed in many cancers including
gastric cancers, and it correlates with both tumor pro-
gression and a poor prognosis. Jackson and colleagues
found that STAT3 activation was more pronounced in
CagA-positive H. pylori-infected gastric tissue [70]. In
this study, as the majority of bacterial pathogens mediate
STAT3 activation via autocrine IL-6, it was found that
IL-6 expression was increased after H. pylori infection,
and both IL-6 and IL-11 were strongly up-regulated in
gastric cancer tissue. In epithelial cells infected with H.
pylori, STAT3 tyrosine phosphorylation, nuclear trans-
location and transcriptional activity are dependent on
unphosphorylated CagA. Although H. pylori CagA-
mediated STAT3 activation requires IL-6 and the gp130
receptor, autocrine activation of STAT3 by IL-6 and IL-
11 is not involved in H. pylori CagA-mediated STAT3
activation [71]. Further studies may be required to eluci-
date the exact mechanism underlying the interaction
between CagA and these relevant receptors. Moreover,
H. pylori-mediated STAT3 activation shows the ability to
manipulate host immunity and facilitate immune evasion
[72, 73]. Recent evidence indicates that CagA increases
the expression of Gram-positive specific bactericidal lec-
tin, regenerating islet-derived (REG) 3γ, in gastric epithe-
lial cells via activation of the STAT3 signaling pathway
[72]. While the functional basis of this response is not
entirely clear, these findings indicate that CagA-medicated
REG3γ overexpression may abolish the fitness of co-
habiting Gram-positive bacteria and reduce the competi-
tion for resources between H. pylori and Gram-positive
bacteria in the gastric mucosal niche. Finally, H. pylori
may rebuild the gastric microbiome and manipulate host
immunity to favor its own survival. The ability to evade
the host immune response is another crucial factor in the
survival of H. pylori in the host gastric mucosae. As DCs
are key modulators of the host adaptive immune response,
they are ideal targets for the pathogen’s immunity-
manipulating efforts. Several studies indicate that H. pylori
infection promotes the development of tolerogenic den-
dritic cells (DCs) in a coculture system and in murine
models [74, 75]. Recently, Rizzuti and colleagues found
that H. pylori activated the STAT3 signaling pathway in
bone marrow-derived DCs (BMDCs). Then BMDCs se-
crete IL-10, which activates STAT3 in DCs, thereby blunt-
ing DC maturation, inducing the tolerogenic DCs [73].
This study describes another novel mechanism of H. pylori
facilitation of immune evasion to maintain its persistence.
The regulation of signaling pathways may be influ-
enced by the CagA tyrosine phosphorylation status. It
has been reported that unphosphorylated CagA showed
preferentially activates of JAK/STAT3, whereas phos-
phorylated CagA enhances SHP2 binding activity and
ERK/MAPK signaling pathway activation [76]. These
findings indicate that the CagA tyrosine phosphorylation
status affects the signal switch, providing a novel mech-
anism explaining H. pylori-mediated signaling pathways.
Unphosphorylated and phosphorylated CagA often exist
at the same time therefore, STAT3 and ERK/MAPK sig-
naling activation must be abnormal during H. pylori
infection. In support of this hypothesis, a research group
observed significantly increased STAT3 and ERK/MAPK
signaling activation in H. pylori-infected gastric tissue,
which was further enhanced in the presence of CagA-
positive H. pylori strains [70]. Recent evidence indicates
that IL-22 promotes gastric cancer development via activa-
tion of the STAT3 and ERK signaling pathways [77]. In this
study, while gastric cancer cells were co-cultured with IL-
22-expressing cancer-associated fibroblasts (CAFs) from
human gastric cancer tissues, the invasive ability of the gas-
tric cancer cells was significantly enhanced through activa-
tion of the STAT3 and ERK signaling pathways. In fact, H.
pylori infection also stimulates peripheral mononuclear
cells and CD4-positive T cells to secrete IL-22, and IL-22
subsequently induces the expression of antimicrobial pro-
teins (eg. RegIIIα and lipocalin-2) in gastric epithelial cells
[78]. In this regard, IL-22 may play a protective role in gas-
tric mucosae infected by H. pylori, but more studies suggest
that IL-22 may lead to pathological inflammation and
thereby promote tumorigenesis and progression via STAT3
activation [77–80]. Th1 and Th17 are major T cell subsets
that produce IL-22, and H. pylori is ability to induce Th1
and Th17 responses [81, 82]. Therefore, it is necessary to
confirm that (i) the role of H. pylori-mediated upregulation
of IL-22 in gastric cancer cells, (ii) the activation of STAT3
dependent on H. pylori-mediated IL-22 and/or H. pylori
CagA, (iii) the role of CagA in H. pylori-mediated upregula-
tion of IL-22.
In addition, H. pylori-mediated signaling (including
p21-activated kinase1 and ERK1/2) to actin-binding pro-
tein cortactin could regulate cell scattering and elong-
ation in a T4SS dependent manner [83, 84]. Injected
CagA further involves in the interaction of cortactin
with downstream focal adhesion kinase (FAK), and this
interaction increases FAK activity, which is important
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for cell scattering and elongation phenotype [83]. Cor-
tactin plays a central role in host signaling and involves
in a variety of cellular processes, including tumorigen-
esis, invasion and metastasis. Thus, further studies may
be required to elucidate the role of H. pylori-hijacked
cortactin in tumorigenesis in vivo. Furthermore, CagA-
positive H. pylori-induced activation of the Src/MEK/
ERK signaling pathway is involved in the upregulation of
α-enolase and ornithine decarboxylase, implying the
progression of gastric diseases [85, 86]. What’s more, H.
pylori is involved in protein kinase C (PKC) signaling
pathway activation through PI3K, phospholipase Cγ and
Ca2+. As a result, PKC contributes to c-Fos upregulation
and activator protein-1 activation, leading to overexpres-
sion of matrix metalloproteinase-1 [87]. Due to the large
number of the related studies, it is difficult to list all of
H. pylori-mediated oncogenic signaling pathways. In
other words, there are several known mechanisms
underlying H. pylori-mediated gastric cancers.
The role of CagA in tumor suppressor pathways
Tumorigenesis is considered to occur as a multifactorial
events. The activation of oncogenes and the inactivation
of tumor suppressor genes are two key events in most
cancers. Aberrant activation of oncogenes can be coun-
teracted by tumor suppressor genes. It is more signifi-
cant to enrich and explain the tumorigenic mechanism
of H. pylori. In addition to activating several oncogenic
signaling pathways, H. pylori also plays a key role in the
inactivation of tumor suppressor pathways. p53 is a key
tumor suppressor, and inactivation of p53 is a critical
step in tumorigenesis and progression. Previous reports
showed that H. pylori infection increased p53 levels in
the gastric mucosae [88–90]. Subsequently, Wei et al.
observed that p53 levels were dynamically altered in H.
pylori-infected mongolian gerbil gastric tissues and cell
lines. Consistent with previous reports, these authors
found that p53 was increased following H. pylori infection
for 4–6 h in mongolian gerbils, however, p53 decreased
rapidly following the initial increase. Interestingly, p53 was
shown to be increased again under continuous H. pylori
infection for 12 weeks [91]. In this study, the authors
confirmed that CagA-positive H. pylori phosphorylated
Human Double Minute 2 (HDM2, a main E3 ubiquitin
ligase), which induced p53 degradation. In addition, H.
pylori-induced phosphorylation and activation of HDM2
could be mediated by Akt or ERK activation (Fig. 2a)
[91, 92]. Cellular stresses, such as H. pylori-induced ac-
tivation of oncogenic signaling pathways, may be re-
sponsible for the initial increase of p53. The second
increase of p53 may be driven by DNA damage known
to be associated with inflammatory processes. In an-
other report, Wei et al. indicated that H. pylori could
induce upregulation of truncated p53 isoforms that in-
hibit p53 function and increase the transcriptional ac-
tivity of NF-κB in gastric epithelial cells (Fig. 2b) [93].
Fig. 2 The role of CagA in p53 regulation. a. CagA phosphorylation and activation of HDM2 is mediated by Akt or ERK activation. b. CagA plays a
crucial role in p53 shifting to inhibitory p53 isoforms. c. CagA-induced hypermethylation of the p14ARF promoter results in a decrease in p14ARF
protein levels that is not sufficient to sequester HDM2 in the nucleus. d. CagA interacts with ASPP2 to recruit and bind p53, which is then degraded by
the proteasome. e. CagA induces aberrant expression of AID via NF-κB and thereby elicits a high mutation frequency in p53
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Taken together, these findings indicate that DNA
damage-mediate upregulation of p53 may be shifted to
inhibitory p53 isoforms by CagA-positive H. pylori. In-
hibition of p53 may allow H. pylori to alter the cellular
homeostasis, without apoptosis or triggering cell cycle
arrest.
The p14ARF is a tumor suppressor that inhibits the
proteasomal degradation of p53 by sequestering HDM2
and inhibiting its E3 ligase activity [94]. H. pylori CagA-
induced hypermethylation of the p14ARF promoter re-
sults in a decrease of p14ARF protein levels that is not
sufficient to inhibit HDM2 and ARF-BP1 (another E3
ubiquitin ligase) activity, and then HDM2 and ARF-BP1
then facilitates the degradation of p53 (Fig. 2c) [95]. This
study provides a novel mechanism in which the CagA-
mediated degradation of p53 is controlled by two E3
ubiquitin ligases that are activated due to p14ARF pro-
moter hypermethylation and downregulation of p14ARF
protein levels. Apoptosis-stimulating protein of p53
(ASPP2) is best known for its role as a p53-binding pro-
tein and has also shown to act as a tumor suppressor.
Following H. pylori infection, CagA shows the ability to
interact with ASPP2 to form a complex. After this inter-
action, ASPP2 recruits and binds p53, which is then de-
graded by the proteasome. Although the formation of a
ternary complex between CagA, ASPP2, and p53 has not
been detected, it has been confirmed that the degradation
of p53 is a consequence of the recruitment and misregula-
tion of ASPP2 by CagA. As a result, CagA-mediated deg-
radation of p53 leads to resistance to apoptosis (Fig. 2d)
[96]. Recently, CagA- and ASPP2-interacting domains have
been identified. The obtained co-crystal structure revealed
that N-terminal subdomain of CagA forms a highly special-
ized three-helix bundle and that ASPP2 forms an extended
helix in this groove of CagA. Consistent with previous
reports, this study provides evidence that the direct inter-
action of CagA and ASPP2 also has an antiapoptotic effect
during H. pylori infection [97].
P53 is inactivated by mutations in 40 %-50 % of gastric
cancers. Individuals infected with CagA-positive H. pyl-
ori show a higher likelihood of harboring p53 mutations
[98, 99]. Activation-induced cytidine deaminase (AID) is
a DNA and RNA mutator enzyme. In vitro studies have
revealed that CagA-positive H. pylori induces aberrant
expression of AID in gastric epithelial cells via NF-κB
activation and thereby elicits a high mutation frequency
in p53 (Fig. 2e) [100]. In addition, AID expression is
elevated in H. pylori-positive human gastric mucosae
and is reduced following H. pylori eradication [101].
A recent study in which whole-exome sequencing
was performed indicated that p53 mutations accumu-
late in patients with H. pylori infection. In this study,
Table 1 CagA-positive H.pylori mediates dysregulation of multiple signaling pathways
Dysregulation of
signaling pathway
Molecular mechanism Proposed function References
Wnt/β-catenin
signaling pathway
Competitive binding E-cadherin Release of β-catenin from the
E-cadherin/β-catenin complex
[22]
Phosphorylation of LRP6 Activation of Dvl [34]
Phosphorylation of Akt Inactivation of GSK-3β and activation
of downstream β-catenin
[37]





Phosphorylation of EGFR Activation of the P13K p85 subunit and
downstream Akt
[37, 48]
Interaction with c-met Activation of P13K/Akt, the downstream
β-catenin and NF-κB
[21]
Interaction with P13K p85 Activation of the P13K p85 subunit and
downstream Akt
[20, 50]
NF-κB signaling pathway Activation of MEK/ERK Phosphorylation of p65, induced the release
of IL-8
[56, 57]
Autophosphorylation of TAK1 Synergy with
phosphorylation of MEKK3
Recruitment and activation of IKK complex [60]
Shh signaling
pathway
Activation of NF-κB Overexpression of Shh
JNK signaling
pathway
Activation of TNF homolog Eiger or
overexpression of Rhol
Upregulation of JNK signaling, induced




Induced IL-6, IL-10 Phosphorylation of STAT3, nuclear translocation
of STAT3
[70–73]
ERK/MAPK signaling pathway Interaction with SHP2, Grb2 and Crk/Crk-L Activation of ERK/MAPK signaling, induced
cell scattering
[19, 20, 76]
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the authors also used AID-transgenic mice to confirm
that AID expression plays a critical role in the accu-
mulation of p53 mutations [102]. These studies pro-
vide a mutation-dependent mechanism of H. pylori-
mediated p53 inactivation.
Similar to p53, (i) Runt-related transcription factor 3
(RUNX3) is also a tumor suppressor, (ii) infection with
CagA-positive H. pylori is associated with inactivation of
RUNX3 in premalignant gastric lesions [103], (iii) CagA
inhibits the expression of RUNX3 via the ERK/MAPK
signaling pathway [104], (iv) CagA may increase the risk
of RUNX3 promoter methylation [105], (v) CagA targets
RUNX3 for ubiquitination and proteasome-mediated
degradation [106]. In addition, the methylation of tumor
suppressor genes is widespread in H. pylori-infected
models. Cheng et al. used integrative genome-wide scans
to identify genes that were concomitantly hypermethy-
lated in mouse and human gastric cancer samples in-
fected with H. pylori. They observed that the promoter
hypermethylation of the Foxd3 tumor suppressor initi-
ated by H. pylori infection affected the prognosis of gas-
tric cancer patients [107]. H. pylori infection causes
gastric mucosal inflammatory responses, resulting in up-
regulation of IL-1β and overproduction of nitric oxide
(NO). IL-1β and NO play an important role in H. pylori-
induced methylation [108, 109]. Here, H. pylori-induced
promoter methylation is observed not only in tumor
suppressor genes but also in microRNAs (miRNAs).
Silencing of these miRNAs promotes tumorigenesis
through activation of their target oncogenes [110]. In
general, CagA can decrease the levels of tumor suppres-
sor proteins or inhibit their activity to inactivate of
tumor suppressor pathways in a variety of ways.
Conclusions
Studies in diverse cell lines and animal models indicate
that CagA is indispensable for H. pylori-induced tumori-
genesis of gastric cancer. CagA acts as an initiator that
activates multiple host cell signaling pathways via direct
or indirect impacts on vital signaling proteins, thereby
leading to signaling pathway-dependent oncogene up-
regulation (Table 1). In addition, CagA also acts as a re-
pressor that inactivates tumor suppressor pathways. As a
result, CagA promotes cell proliferation, transdifferentia-
tion and reduces apoptosis, which is beneficial to
tumorigenesis. Furthermore, CagA induces cell polarity
and morphogenic changes, such as cell motility and scat-
tering (known as the ‘hummingbird phenotype’) and the
epithelial-mesenchymal transition, promoting develop-
ment of gastric cancer. Accordingly, current guidelines
strongly recommend treatments aimed at H. pylori
eradication to prevent gastric cancer. However, few indi-
viduals infected by H. pylori may develop gastric cancer.
Therefore, targeted CagA-positive H. pylori eradication
may be more suitable for current personalized treatment
strategies. A CagA detection kit has been used in clinical
practice, but it is regrettable that there are currently no
drugs that target CagA-positive H. pylori. On the other
hand, the H. pylori-infected population is susceptible,
and these individuals are easily reinfected with H. pylori
after H. pylori eradication. H. pylori has coevolved along-
side humans to promote persistent colonization of gas-
tric mucosae. Focusing on the pathways implicated in
H. pylori-induced tumorigenesis may lead to novel thera-
peutic strategies for gastric cancer prevention.
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